◉ Summary of Use during Lactation:Because of the high serum levels found in some breastfed infants, possible infant side effects, and the possible negative effects on lactation, other antihypertensive agents are preferred, especially while nursing a newborn or preterm infant. Clonidine used as a single postpartum dose as a neuraxial analgesia adjunct probably has not been studied, but it may reduce the need for other medications or their dosages, and appears unlikely to affect breastfeeding.
◉ Effects in Breastfed Infants:No typical clonidine side effects (e.g., dry mouth, sedation) were seen in 9 infants whose mothers were taking clonidine, despite the infants' serum levels being about half that of their mothers'.
Three infants whose mothers were taking clonidine 150 mcg twice daily were breastfed. During the first 3 days postpartum, no adverse effects on blood glucose, electrocardiogram or blood pressure. The infants had normal growth and psychomotor development at 1 year of age, although the duration of breastfeeding and clonidine use was not stated.
An infant was born to a mother taking clonidine 0.15 mg daily during pregnancy and postpartum. At 2 days of life, the infant presented with drowsiness, hypotonia, and suspected generalized seizures. At day 5, episodes of apnea were noted. On day 9 postpartum, breastfeeding was stopped and all symptoms resolved within 24 hours. Clonidine was probably the cause of the reaction, but the relative contributions of exposure during pregnancy and breastfeeding cannot be determined.
◉ Effects on Lactation and Breastmilk:Clonidine has complex, dose-related effects on both oxytocin and prolactin secretion. The net effect of the drug on nursing mothers has not been well studied. A case of hyperprolactinemia and gynecomastia occurred in a 6-year-old boy taking clonidine for hyperactivity and valproic acid for a seizure disorder. Galactorrhea ceased within 3 weeks of discontinuing clonidine. A case of clonidine-induced postpartum galactorrhea has also been reported. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Substituted 1,3-thiazole compounds, their production and use
申请人:——
公开号:US20040053973A1
公开(公告)日:2004-03-18
(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.
The present invention relates to compounds of formula I
wherein R
1
to R
4
and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
The present invention relates to compounds of formula I
wherein A and R
1
to R
4
are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES
申请人:Mohr Peter
公开号:US20090029976A1
公开(公告)日:2009-01-29
The present invention relates to compounds of formula I
wherein X, A and R
1
to R
4
are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF
申请人:Tsai Guochuan Emil
公开号:US20190112289A1
公开(公告)日:2019-04-18
The present invention relates to compounds of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent
is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L
1
and L
2
, independently, is a moiety selected from O, CH
2
, C═O, C
2-10
alkyl, C
2-10
alkenyl, C
2-10
alkynyl, —((CH
2
)
n
—W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L
2
is absent, Z is aryl or heteroaryl fused with B
C. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).
本发明涉及以下式(I)的化合物:
或其药学上可接受的盐,其中:A、B、C、D 和 E 中的每一个独立地是 C、N、N—H、O、S 或不存在
是单键或双键;X、Y 和 Z 中的每一个独立地是芳基、杂环芳基、芳基烷基、H 或不存在;L
1
和 L
2
中的每一个独立地是从 O、CH
2
、C═O、C
2-10
烷基、C
2-10
烯基、C
2-10
炔基、—((CH
2
)
n
—W)— 中选择的基团,其中 n=0、1、2、3、4 或 5,W 是 O 或 S,或不存在;当 L
2
不存在时,Z 是与 B 相融合的芳基或杂环芳基。本发明还提供了一种用于抑制、治疗和/或减少神经精神障碍风险的方法,包括向需要的受试者施用包含式(I)化合物的组合物。